Qualigen Therapeutics (Qualigen Therapeutics) Momentum Rank : 1 (As of May. 15, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Qualigen Therapeutics Momentum Rank?

Qualigen Therapeutics has the Momentum Rank of 1.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Qualigen Therapeutics's Momentum Rank

For the Biotechnology subindustry, Qualigen Therapeutics's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Qualigen Therapeutics's Momentum Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Qualigen Therapeutics's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Qualigen Therapeutics's Momentum Rank falls into.

Qualigen Therapeutics Momentum Rank Related Terms

Thank you for viewing the detailed overview of Qualigen Therapeutics's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Qualigen Therapeutics (Qualigen Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qualigen Therapeutics Inc (NAS:QLGN) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

7R9:Germany

Address

2042 Corte del Nogal, Suite B, Carlsbad, CA, USA, 92011

Website

https://www.qualigeninc.com

Qualigen Therapeutics Inc is a biotechnology company focused on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases using nanoparticle coating technology. It is a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug designation, while also commercializing diagnostics. The Company has viewed its operations and managed its business in one segment operating mainly within the United States and Israel.

Executives

Michael S. Poirier	director, officer: Chairman, President and CEO	2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Amy S. Broidrick	director	1440 VALLE GRANDE, ESCONDIDO CA 92025
Kurt H Kruger	director	100 FOXBOROUGH BLVD, SUITE 240, FOXBOROUGH MA 02035
Tariq Arshad	officer: SVP/Chief Medical Officer	2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Christopher L. Lotz	officer: Vice President of Finance, CFO	2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 90211
Emery Sidney W Jr	director	C/O QUALIGEN THERAPEUTICS, INC., 2042 CORTE DEL NOGAL, CARLSBAD CA 92011
Richard A. David	director	2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Wajdi Abdul-ahad	officer: VP, R&D, CSO	2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Shishir K. Sinha	officer: VP of Operations	2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Sekisui Diagnostics, Llc	10 percent owner	1 WALL STREET, BURLINGTON MA 01803
Matthew E Korenberg	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Noah Doyle	director	C/O RITTER PHARMACEUTICALS INC., 1801 CENTURY PARK EAST, SUITE 1820, LOS ANGELES CA 90096
John W Beck	officer: Chief Financial Officer	C/O RITTER PHARMACEUTICALS, INC., 1880 CENTURY PARK EAST, SUITE 1000, LOS ANGELES CA 90067
Jeffrey S Benjamin	officer: VP of Finance	3885 CRESTWOOD PARKWAY, SUITE 550, DULUTH GA 30096
William M. Merino	director	C/O RITTER PHARMACEUTICALS INC., 1880 CENTURY PARK EAST, SUITE 1000, LOS ANGELES CA 90067